The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 12, 2026
Filed:
Sep. 02, 2025
Applicant:
Odyssey Therapeutics, Inc., Boston, MA (US);
Inventors:
Chad Vanhuis, Hartland, MI (US);
Shifeng Pan, San Diego, CA (US);
Dominik K. Koelmel, Ann Arbor, MI (US);
Robert Aversa, Watertown, MA (US);
Clarke Taylor, Ann Arbor, MI (US);
Marta Wlodarska, Cambridge, MA (US);
Assignee:
Odyssey Therapeutics, Inc., Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/4995 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); A61K 31/541 (2006.01); A61K 31/675 (2006.01); C07B 59/00 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 451/06 (2006.01); C07D 487/08 (2006.01); C07D 491/107 (2006.01); C07D 498/08 (2006.01); C07F 9/6558 (2006.01); C07F 9/6568 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/4995 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61K 31/541 (2013.01); A61K 31/675 (2013.01); C07B 59/002 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 451/06 (2013.01); C07D 487/08 (2013.01); C07D 491/107 (2013.01); C07D 498/08 (2013.01); C07F 9/65583 (2013.01); C07F 9/65685 (2013.01); C07K 16/2839 (2013.01);
Abstract
The present disclosure relates to RIPK2 inhibitors represented by structural formula (I): The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.